IL17RA and psoriasis: Fully human monoclonal antibodies (mAbs) against IL-17 (ixekizumab and secukinumab) and IL-17 receptor A (IL-17RA) (brodalumab) have rapidly reduced clinical symptoms in patients with psoriasis [14–18].